1
|
Elkhamary A, Gerner I, Bileck A, Oreff GL, Gerner C, Jenner F. Comparative proteomic profiling of the ovine and human PBMC inflammatory response. Sci Rep 2024; 14:14939. [PMID: 38942936 PMCID: PMC11213919 DOI: 10.1038/s41598-024-66059-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2024] [Accepted: 06/26/2024] [Indexed: 06/30/2024] Open
Abstract
Understanding the cellular and molecular mechanisms of inflammation requires robust animal models. Sheep are commonly used in immune-related studies, yet the validity of sheep as animal models for immune and inflammatory diseases remains to be established. This cross-species comparative study analyzed the in vitro inflammatory response of ovine (oPBMCs) and human PBMCs (hPBMCs) using mass spectrometry, profiling the proteome of the secretome and whole cell lysate. Of the entire cell lysate proteome (oPBMCs: 4217, hPBMCs: 4574 proteins) 47.8% and in the secretome proteome (oPBMCs: 1913, hPBMCs: 1375 proteins) 32.8% were orthologous between species, among them 32 orthologous CD antigens, indicating the presence of six immune cell subsets. Following inflammatory stimulation, 71 proteins in oPBMCs and 176 in hPBMCs showed differential abundance, with only 7 overlapping. Network and Gene Ontology analyses identified 16 shared inflammatory-related terms and 17 canonical pathways with similar activation/inhibition patterns in both species, demonstrating significant conservation in specific immune and inflammatory responses. However, ovine PMBCs also contained a unique WC1+γδ T-cell subset, not detected in hPBMCs. Furthermore, differences in the activation/inhibition trends of seven canonical pathways and the sets of DAPs between sheep and humans, emphasize the need to consider interspecies differences in translational studies and inflammation research.
Collapse
Affiliation(s)
- A Elkhamary
- Department for Companion Animals and Horses, Veterm, University Equine Hospital, Vetmeduni Vienna, Vienna, Austria
- Department for Surgery, Faculty of Veterinary Medicine, Damanhour University, Damanhour, Egypt
| | - I Gerner
- Department for Companion Animals and Horses, Veterm, University Equine Hospital, Vetmeduni Vienna, Vienna, Austria
- Austrian Cluster for Tissue Regeneration, Vienna, Austria
| | - A Bileck
- Department of Analytical Chemistry, Faculty of Chemistry, University of Vienna, Vienna, Austria
| | - G L Oreff
- Department for Companion Animals and Horses, Veterm, University Equine Hospital, Vetmeduni Vienna, Vienna, Austria
| | - C Gerner
- Department of Analytical Chemistry, Faculty of Chemistry, University of Vienna, Vienna, Austria
| | - F Jenner
- Department for Companion Animals and Horses, Veterm, University Equine Hospital, Vetmeduni Vienna, Vienna, Austria.
- Austrian Cluster for Tissue Regeneration, Vienna, Austria.
| |
Collapse
|
2
|
Yang J, Zhao Y, Fu Y, Lv Y, Zhu Y, Zhu M, Zhao J, Wang Y, Wu C, Zhao W. Recombinant antigen P29 of Echinococcus granulosus induces Th1, Tc1, and Th17 cell immune responses in sheep. Front Immunol 2023; 14:1243204. [PMID: 38187382 PMCID: PMC10768560 DOI: 10.3389/fimmu.2023.1243204] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2023] [Accepted: 11/22/2023] [Indexed: 01/09/2024] Open
Abstract
Echinococcosis is a common human and animal parasitic disease that seriously endangers human health and animal husbandry. Although studies have been conducted on vaccines for echinococcosis, to date, there is no human vaccine available for use. One of the main reasons for this is the lack of in-depth research on basic immunization with vaccines. Our previous results confirmed that recombinant antigen P29 (rEg.P29) induced more than 90% immune protection in both mice and sheep, but data on its induction of sheep-associated cellular immune responses are lacking. In this study, we investigated the changes in CD4+ T cells, CD8+ T cells, and antigen-specific cytokines IFN-γ, IL-4, and IL-17A after rEg.P29 immunization using enzyme-linked immunospot assay (ELISPOT), enzyme-linked immunosorbent assay (ELISA), and flow cytometry to investigate the cellular immune response induced by rEg.P29 in sheep. It was found that rEg.P29 immunization did not affect the percentage of CD4+ and CD8+ T cells in peripheral blood mononuclear cells (PBMCs), and was able to stimulate the proliferation of CD4+ and CD8+ T cells after immunization in vitro. Importantly, the results of both ELISPOT and ELISA showed that rEg.P29 can induce the production of the specific cytokines IFN-γ and IL-17A, and flow cytometry verified that rEg.P29 can induce the expression of IFN-γ in CD4+ and CD8+ T cells and IL-17A in CD4+ T cells; however, no IL-4 expression was observed. These results indicate that rEg.P29 can induce Th1, Th17, and Tc1 cellular immune responses in sheep against echinococcosis infection, providing theoretical support for the translation of rEg.P29 vaccine applications.
Collapse
Affiliation(s)
- Jihui Yang
- Center of Scientific Technology of Ningxia Medical University, Yinchuan, China
- Ningxia Key Laboratory of Prevention and Treatment of Common Infectious Diseases of Ningxia Medical University, Yinchuan, China
| | - Yinqi Zhao
- Center of Scientific Technology of Ningxia Medical University, Yinchuan, China
- Ningxia Key Laboratory of Prevention and Treatment of Common Infectious Diseases of Ningxia Medical University, Yinchuan, China
| | - Yong Fu
- Qinghai Academy of Animal Sciences and Veterinary Medicine, Qinghai University, Xining, China
| | - Yongxue Lv
- Ningxia Key Laboratory of Prevention and Treatment of Common Infectious Diseases of Ningxia Medical University, Yinchuan, China
- School of Basic Medicine, Ningxia Medical University, Yinchuan, China
| | - Yazhou Zhu
- Ningxia Key Laboratory of Prevention and Treatment of Common Infectious Diseases of Ningxia Medical University, Yinchuan, China
- School of Basic Medicine, Ningxia Medical University, Yinchuan, China
| | - Mingxing Zhu
- Center of Scientific Technology of Ningxia Medical University, Yinchuan, China
- Ningxia Key Laboratory of Prevention and Treatment of Common Infectious Diseases of Ningxia Medical University, Yinchuan, China
| | - Jiaqing Zhao
- Center of Scientific Technology of Ningxia Medical University, Yinchuan, China
- Ningxia Key Laboratory of Prevention and Treatment of Common Infectious Diseases of Ningxia Medical University, Yinchuan, China
| | - Yana Wang
- Ningxia Key Laboratory of Prevention and Treatment of Common Infectious Diseases of Ningxia Medical University, Yinchuan, China
- School of Basic Medicine, Ningxia Medical University, Yinchuan, China
| | - Changyou Wu
- Institute of Immunology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China
| | - Wei Zhao
- Center of Scientific Technology of Ningxia Medical University, Yinchuan, China
- Ningxia Key Laboratory of Prevention and Treatment of Common Infectious Diseases of Ningxia Medical University, Yinchuan, China
| |
Collapse
|